

Clinical trials for advancing innovative interventions for neurodegenerative diseases

Horizon Europe

● IN ATTESA

Codice	Ambito
HORIZON-HLTH-2027-02-DISEASE-14-two-stage	Internazionale
Località	Curatore
Europa	Marlene Faria

DETTAGLI FINANZIARI

Tipo di supporto	Budget
Fondo perduto	39.3M€
Valore di Progetto Ammissibile	
Up to 10M€	

DATE E SCADENZE

Data di Pubblicazione	Data di Apertura
19 ottobre 2026	29 ottobre 2026
Fase 1	Fase 2
17 febbraio 2027 alle ore 17:00 GMT+1	16 settembre 2027 alle ore 17:00 GMT+2

DESCRIZIONE

Objectives

This topic aims to advance innovative therapeutic interventions for non-rare neurodegenerative diseases through rigorous early-stage clinical trials. Given that many existing treatments primarily address symptoms and may have significant side effects, projects should develop safer and more effective interventions that target underlying disease mechanisms, improve patients' quality of life and reduce the burden on caregivers, healthcare systems and society.

The proposed intervention should combine a therapy based on an active substance with a complementary multidisciplinary approach, such as lifestyle changes, cognitive training or rehabilitation. Rare neurodegenerative diseases are excluded from the scope of the topic.

Funding

The topic has an indicative total budget of €39.3 million, with an expected EU contribution of approximately €10 million per project. Funding is provided under Horizon Europe as a Research and Innovation Action (RIA), normally covering 100% of eligible costs, plus the applicable flat rate for indirect costs. The call follows a two-stage submission procedure, with deadlines currently indicated as 17 February 2027 for the first stage and 16 September 2027 for the second stage. Proposals should also allocate sufficient resources for participation in joint networking, coordination and dissemination activities at European level.

SPESE AMMISSIBILI

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

IDONEITÀ

Modalità di Candidatura

Aggregata / Partenariato

Settori Idonei

- Salute e Life Sciences
- ICT e Software

Tipologie Aziendali

- Microimpresa
- PMI
- Grande impresa
- Enti privati non profit
- Enti pubblici

Tipi di Azione

- Clinical trials
- Technological innovation
- Data integration
- Societal engagement
- Health research collaboration
- Research and Innovation Action

DETTAGLI PROGRAMMA UE

ID Bando	Cluster
HORIZON-HLTH-2027-02-DISEASE-14-two-stage	Health
Destinazione	Modalità di Presentazione
Tackling diseases and reducing disease burden	Two-stage
Contributo UE	Progetti Previsti
Around €10,000,000.00 per project	4
Regola del Tasso di Finanziamento	
Up to 100% of eligible costs for Research and Innovation Actions (RIA)	

LINK UFFICIALI

Regolamento Ufficiale

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-02-DISEASE-14-two-stage?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2027-02-DISEASE-14-two-stage&isExactMatch=true&status=31094501,31094502,31094503>

Pagina Grantavia

<https://grantavia.com/it/incentives/clinical-trials-for-advancing-innovative-interventions-for-neurodegenerative-diseases>

Prenota un incontro

<https://bookings.cloud.microsoft/book/Prenotaunappuntamento@epsa.com/?ismsaljsauthenabed>